



Tesamorelin to be Assessed in the Treatment of Liver Disease in HIV-Infected Patients

June 9, 2015

Theratechnologies (TSX: TH) today announced a collaboration with the Massachusetts General Hospital (MGH) that will evaluate the safety and efficacy of tesamorelin in the treatment of HIV-infected patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Tesamorelin is not indicated for either of these conditions.